Intermediate and high-risk localised, completely resected, gastrointestinal stromal tumours (GIST) expressing KIT receptor: a controlled randomised trial of adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery.
Imatinib mesylate is highly effective for advanced, unresectable gastrointestinal stromal tumours. However, its long-term effect on survival outcomes remains unclear. This study will compare the effect of adjuvant imatinib mesylate versus observation only on the prognosis of patients with completely resected localised gastrointestinal stromal tumours at intermediate or high risk of relapse.
Novartis Pharmaceuticals Australia; AGITG
Patients with intermediate- and high-risk localised, completely resected, gastrointestinal stromal tumours.